Quantcast
Last updated on April 24, 2014 at 12:23 EDT

Latest Oncolytics Biotech Inc. Stories

2012-02-21 06:00:00

CALGARY, Feb. 21, 2012 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has entered into an agreement whereby the NCIC Clinical Trials Group (CTG) at Queen's University in Kingston, Ontario, will sponsor and conduct a randomized Phase II study of REOLYSIN(®) in patients with recurrent or metastatic castration resistant prostate cancer. "Third party sponsored trials remain an important part of our overall clinical strategy. We...

2011-12-02 06:00:00

CALGARY, Dec. 2, 2011 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC) (NASDAQ:ONCY) ("Oncolytics") today announced that interim data from a Phase 2 clinical trial using intravenous administration of REOLYSIN(® )in combination with gemcitabine (Gemzar(®)) in patients with advanced pancreatic cancer (REO 017) indicated that the clinical study had successfully reached its primary endpoint, and that the drug combination is active. To date, eight...

2011-11-21 06:00:00

CALGARY, Nov. 21, 2011 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced that SAFC, a Division of Sigma-Aldrich Corporation, has commenced validation activities designed to demonstrate the manufacturing process for the commercial production of REOLYSIN(®), Oncolytics' proprietary formulation of reovirus, is robust and reproducible. Process validation is required to ensure that the resulting product meets...

2011-11-14 06:00:00

CALGARY, Nov. 14, 2011 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics") today announced that interim results from a Phase 2 clinical trial using intravenous administration of REOLYSIN(® )in combination with gemcitabine (Gemzar(®)) in patients with advanced pancreatic cancer will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The conference is being held in San...

2011-11-14 06:00:00

CALGARY, Nov. 14, 2011 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that positive results from a Phase 2 clinical trial (REO 015) using intravenous administration of REOLYSIN(®) in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The conference is being held in San...

2011-11-11 15:00:00

CALGARY, Nov. 11, 2011 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics") today announced that Dr. Brad Thompson, President and CEO of Oncolytics, will host a conference call and webcast on Monday, November 14(th), 2011 at 6:30 a.m. MT (8:30 a.m. ET) to discuss in more depth clinical data being presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference being held in San Francisco, CA from November 12(th) to 16(th), 2011. To access...

2011-11-10 06:10:00

CALGARY, Nov. 10, 2011 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC) (NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the quarter ended September 30, 2011. "During the quarter we achieved significant increases in the number of enrolling countries in the first stage of our Phase III head and neck cancer study," said Dr. Brad Thompson, President and CEO of Oncolytics. "We currently have approval to conduct the trial...

2011-11-10 06:00:00

CALGARY, Nov. 10, 2011 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics") today announced the appointment of Gerard Kennealey, MD as Senior Vice President of Clinical Development and Chief Medical Officer (CMO). George M. Gill, MD, Oncolytics' CMO since July 2011, will return to his previous role as Senior Vice President of Regulatory Affairs and also has been appointed Chief Safety Officer. "Dr. Kennealey is an excellent addition to our clinical development...

2011-09-22 06:00:00

CALGARY, Sept. 22, 2011 /PRNewswire/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC) (NASDAQ: ONCY), will present a corporate overview of the Company at the JMP Securities Healthcare Conference on Wednesday, September 28(th), 2011 at 12:30 p.m. ET. The conference will take place on September 27(th) and 28(th) at the St. Regis New York Hotel in New York, NY. A live audio link to the webcast presentation will be available at:...

2011-08-11 06:00:00

CALGARY, Aug. 11, 2011 /PRNewswire/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC) (NASDAQ: ONCY), will present a corporate overview of the Company at the Wedbush 2011 Life Sciences Management Access Conference on Tuesday, August 16(th), 2011 at 8:35 a.m. ET. The conference will take place from August 16(th) to 17(th) at the Le Parker Meridien Hotel in New York, NY. A live audio link to the webcast presentation will be available at:...